| Sector |
Consumer Healthcare
|
|---|---|
| Region |
Altrincham
|
| Stage |
Growth
|
| Fund | Life Sciences EIS |
Founded to develop and produce quality therapeutic mattresses for use in the global market.
The Investment Opportunity
The Company’s new foam products directly address poor body alignment and posture whilst a person is in bed. In a medical capacity, failure to address poor posture can significantly exacerbate a patient’s medical condition and can lead to issues such as pressure sores and possible sleep deprivation. The result of which can worsen the patient’s condition, often leading to lengthy and therefore more costly stays in hospital.
After initially focusing on the healthcare market, the Company has now pivoted its strategy to focusing on the retail consumer sector, with their market research and successful early traction of the product demonstrating this sector is much more accessible and lucrative.
The Company sees a real opportunity globally to re-think orthopaedics mattresses. By using the very latest foam material combined with the latest scientific research, it can cement its brand into a growing market whilst actively seeking solutions to what is a costly problem.
Milestones to Date
| 2017 | Deepbridge initially invested £150k via the Deepbridge Life Sciences SEIS. |
|---|---|
| 2019 | 2nd clinical study completed at the University of Central Lancashire, which was funded by ERDF (European Regional Development Fund). Successfully closed Kickstarter funding round. |
Risks and Important Information
This page is a financial promotion for the purposes of Section 21 of the Financial Services and Markets Act 2000. The content of the page has been approved by Deepbridge Capital LLP. The Company may not gain the commercial traction that is forecast, it could experience development problems and may not be able to achieve its objectives. Please note that these risks are by no means exhaustive and there may be other risks which could have a material adverse impact on the Company’s financial performance. The content should not be construed as financial advice. Any decision to invest should be made only on the basis of the relevant documentation for each investment. Past performance is not necessarily a guide to future performance. The value of an investment may go down as well as up and investors could lose the total value of their investment. Investments in small unquoted companies carry a high- level of risk. These investments are highly illiquid and as such, there may not be a readily available market to sell such an investment. Tax treatment depends on the individual circumstances of each investor and may be subject to change in future. The availability of tax reliefs depends on the Company invested in maintaining its qualifying status. Deepbridge does not provide specific individual advice on the suitability of investments with regard to a potential investor’s individual circumstances, risk tolerance or investment objectives and investors should seek independent financial advice if they are in any doubt whether a product is suitable for them.
About Levitex Ltd.:
Levitex is the brainchild of founder James Leinhardt, who has spent 10+ years helping the critically injured, the chronically ill, and the in-firm patients and has learnt a key fact.
Whether it comes to complex neurological patients, elite athletes, home office workers, and everyone in the middle, the impact of sleep quality, and specifically what we sleep on, can’t be underestimated.
So, James took the science that he learnt in healthcare and applied it to creating the optimum lying surface. One that considers not just comfort and pressure relief, but also support and posture. Something that’s almost a cheat to getting a good night’s sleep. He called it Levitex.
- - -
Supporting growth-focused companies and entrepreneurs has never been more important, but it is important to understand the people and ideas behind such investment opportunities.
Join the Deepbridge Capital team each week as they discuss all things Deepbridge, speak with various investment experts within the company and discover more about the founders and CEOs’ running the portfolio companies Deepbridge invests in. Each episode contains an informal conversation to understand how these leaders and teams perform in order to achieve their goals. Investments in early-stage companies are illiquid and high risk – investors could lose all of their capital.